TABLE 1.
Disposition of patients
| Populationa or detail | No. (%) treated with:
|
|
|---|---|---|
| Linezolid | Oxacillin-dicloxacillin | |
| ITT patients | 400 (100) | 419 (100) |
| Clinically evaluable patients | 298 (74.5) | 302 (72.1) |
| Reasons for nonevaluability: | ||
| Prior antibiotic usage | 3 (0.8) | 4 (1.0) |
| Insufficient therapy | 29 (7.3) | 43 (10.3) |
| Concomitant antibiotics | 11 (2.8) | 15 (3.6) |
| Noncompliance with regimen | 39 (9.8) | 47 (11.2) |
| No clinical outcome postbaseline | 64 (16.0) | 64 (15.3) |
| Microbiologically evaluable patients | 143 (35.8) | 151 (36.0) |
| Reasons for nonevaluability: | ||
| Clinically nonevaluable | 102 (25.5) | 117 (27.9) |
| No baseline pathogens | 189 (47.3) | 201 (48.0) |
| Baseline pathogen resistant to study medication | 11 (2.8) | 11 (2.6) |
a
Patients may have had multiple reasons for nonevaluability. All reasons are summarized; therefore, percentages may total more than 100%.